Equity Research
William Blair research analyst Dylan Carden was quoted in Business of Fashion, where he discussed why end-consumers haven’t as of June 2025 felt a substantive financial impact of the Trump administration’s tariffs.
“Right now, it’s…a game of chicken. But my research has called into question how much prices can go up,” Carden told the publication.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Contineum Therapeutics, Inc. (CTNM $3.93), a clinical-stage biotech developing small-molecule therapeutics for high-unmet-need indications in the prevalent neuroinflammation and immunology space.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
